DCAF12L1: Potential Drug Target and Biomarker for Alzheimer's Disease

Target Name: DCAF12L1

NCBI ID: G139170

DCAF12L1

DCAF12L1: Potential Drug Target and Biomarker for Alzheimer's Disease

DCAF12L1 (OTTHUMP00000023979) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is composed of 214 amino acids and has a calculated molecular weight of 23.5 kDa. It is found in the endoplasmic reticulum (ER) and is expressed in the brain, as well as other tissues and organs.

The search for potential drug targets and biomarkers is a critical aspect of modern medicine. Alzheimer's disease is a neurodegenerative disorder that affects millions of people worldwide, and there is currently no cure. Therefore, the development of new drug targets and biomarkers is of great interest. DCAF12L1 is a protein that has been identified as a potential drug target and biomarker for Alzheimer's disease.

DCAF12L1 is involved in the development and progression of Alzheimer's disease

Alzheimer's disease is a neurodegenerative disorder that is characterized by the progressive accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain. These tangles and plaques are thought to contribute to the neurodegeneration that occurs in Alzheimer's disease. DCAF12L1 has been shown to be involved in the development and progression of Alzheimer's disease.

One of the hallmarks of Alzheimer's disease is the accumulation of beta-amyloid plaques in the brain. Beta-amyloid plaques are composed of abnormally modified proteins that are thought to contribute to the neurofibrillary tangles that are observed in Alzheimer's disease. DCAF12L1 has been shown to be involved in the production and degradation of beta-amyloid plaques.

In addition to its role in the production and degradation of beta-amyloid plaques, DCAF12L1 has also been shown to be involved in the regulation of the neurotransmitter dopamine. DCAF12L1 is a dopamine transporter, which means that it is involved in the transport of dopamine from the brain to other tissues and organs. DCAF12L1 has been shown to play a role in the regulation of dopamine levels in the brain, which may be important for the function of the brain.

DCAF12L1 is a potential drug target for Alzheimer's disease

The development of new drug targets and biomarkers is an important step in the development of new treatments for Alzheimer's disease. DCAF12L1 is a protein that has been identified as a potential drug target and biomarker for Alzheimer's disease. The following are some potential strategies for the development of DCAF12L1 as a drug target:

1. Chemical inhibition: One potential strategy for the development of a drug that blocks the activity of DCAF12L1 is to synthesize small molecules that inhibit the activity of DCAF12L1. These small molecules could be used to treat Alzheimer's disease by reducing the production and/or the function of beta-amyloid plaques and increasing the levels of dopamine in the brain.
2. Targeted delivery: Another potential strategy for the development of a drug that blocks the activity of DCAF12L1 is to deliver small molecules directly to the brain. This could be done using techniques such as nanoparticles or gene therapy, which allow for the delivery of small molecules directly to the target cells.
3. blockade of DCAF12L1's activity: Another approach could be to block the activity of DCAF12L1 by using antibodies that specifically bind to the protein. This could allow for the targeting of DCAF12L1 in the brain and to inhibit its activity.

DCAF12L1 is also a potential biomarker for

Protein Name: DDB1 And CUL4 Associated Factor 12 Like 1

The "DCAF12L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DCAF12L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets